snowball82 Posted December 23, 2016 Share Posted December 23, 2016 NIGHT THERAPEUTICS COMPLETES PREVIOUSLY ANNOUNCED BOUGHT DEAL OF COMMON SHARES, INCLUDING EXERCISE OF OVER-ALLOTMENT OPTION, FOR $100 MILLION Long Zone Holdings Inc., a company controlled by Jonathan Ross Goodman, chief executive officer of the company, purchased 25,000 common shares under the offering. Samira Sakhia, president of the company, and Jeffrey Kadanoff, chief financial officer of the company, each purchased 10,000 common shares, and Amal Khouri, vice-president of business development of the company, purchased 5,000 common shares. http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aGUD-2432602&symbol=GUD®ion=C Link to comment Share on other sites More sharing options...
snowball82 Posted December 29, 2016 Share Posted December 29, 2016 GUD announced today a $2 M investment + warrants in SNYR. Gud will own close 20 % of the company after the closing. GUD has $ 650 M of available cash ($ 740 M of cash - $ 90 M committed as investment in life science funds). Let called the announce not the elephant we are waiting for ! Link to comment Share on other sites More sharing options...
snowball82 Posted May 8, 2017 Share Posted May 8, 2017 The new presentation is available. http://www.gud-knight.com/images/presentation/2017-05-01-Knight-Corporate-Presentation-May-2017-vF.pdf $736 m cash ($6.86 / share) and high growth countries -with expanding access and funding for medicines- targeted. AGM Tuesday. Link to comment Share on other sites More sharing options...
Drokos Posted May 8, 2017 Share Posted May 8, 2017 Too much cash to put to work at consistently high rates. Canadian pharma market is not that big. If he doesn't buy Paladin back, or some large assets off of Valeant, it will take them 5+ years to put all that money to work on good deals. The cash will just be sitting idle for so long the total shareholder return wont be very impressive. If I had the opportunity to buy in at book value of Jonathan starting a company with $50m of cash, I would do it all day. The same opportunity at $1 billion is not quite as appealing. His first ~$50 million will be put to work at very high returns, but there are only so many deals. The weighted average return will be significantly dragged down if you are trying to put $1 billion to work. Link to comment Share on other sites More sharing options...
snowball82 Posted May 8, 2017 Share Posted May 8, 2017 Too much cash to put to work at consistently high rates. Canadian pharma market is not that big. If he doesn't buy Paladin back, or some large assets off of Valeant, it will take them 5+ years to put all that money to work on good deals. The cash will just be sitting idle for so long the total shareholder return wont be very impressive. Maybe you are right Drokos and we should sell. That said I think I will be patient. Very patient. Link to comment Share on other sites More sharing options...
no_free_lunch Posted December 19, 2017 Share Posted December 19, 2017 This is down near 52 week lows. It is sitting at $7.82 and they raised capital a year ago at $10. I don't see anything too negative happening. The situation just "seems" stagnant and I think investors are getting bored. It is sitting at about 1.1x book. It feels like a reasonable multiple given they are only about 25% capital deployed. However, compared to the rest of the market this seems like a safer way to get a decent rate of return. Link to comment Share on other sites More sharing options...
Liberty Posted July 6, 2018 Share Posted July 6, 2018 https://globenewswire.com/news-release/2018/07/06/1534131/0/en/Knight-Receives-Adverse-Notice-of-Reassessment-from-CRA.html MONTREAL, July 06, 2018 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has received a notice of reassessment ("CRA Notice") from the Canada Revenue Agency ("CRA") for its fiscal year ended December 31, 2014. The CRA Notice relates to the disposition of the Priority Review Voucher ("PRV") granted on March 19, 2014, upon the US Food & Drug Administration's ("FDA") approval of Impavido®. The PRV was disposed of by Knight's wholly-owned subsidiary, Knight Therapeutics (Barbados) Inc. ("KTB"), to a third party in November 2014 for gross proceeds of US$125 million. The proceeds have contributed to the development of the business operations of KTB, including the out-licensing of Impavido®, as well as business development strategies designed to acquire additional pharmaceutical product rights. The CRA Notice provides that Knight is liable to pay to the CRA an aggregate of $23.3 million in additional taxes and interest. It is likely that the Quebec Revenue Agency ("QRA") will propose a similar adjustment which will result in an estimated additional tax liability of $19.0 million increasing the total additional taxes, interest and penalties to $42.3 million ("Total Tax Liability"). Knight believes that the CRA Notice is unfounded and intends to contest vigorously the CRA Notice by filing a notice of objection to start the appeals process. However, there can be no assurance regarding the outcome of the appeals process or when a resolution may be reached. In connection with the appeals process, Knight has made a deposit of $23.3 million to the CRA and will make an estimated deposit of $19.0 million to QRA. Knight has not recorded any tax provision for the Total Tax Liability in its financial statements. Although Knight believes its tax provisions are adequate, the final determination of tax audits and any related disputes could be materially different from historical income tax provisions and accruals. Link to comment Share on other sites More sharing options...
snowball82 Posted September 24, 2018 Share Posted September 24, 2018 Good news, another close to $ 20 M deal. Patient investors, yes we are. https://www.nasdaq.com/press-release/knight-therapeutics-and-jaguar-health-announce-strategic-partnership-20180924-01070 Link to comment Share on other sites More sharing options...
snowball82 Posted October 22, 2018 Share Posted October 22, 2018 Updates for the very VERY patients investors :) Investing is boring http://www.gud-knight.com/wp-content/uploads/KTI_Corporate_Presentation_August_2018.pdf https://www.nasdaq.com/press-release/knight-therapeutics-and-jaguar-health-announce-strategic-partnership-20180924-01070 Link to comment Share on other sites More sharing options...
snowball82 Posted November 12, 2018 Share Posted November 12, 2018 New presentation. Probuphine lauched in Q4 2018. Ibsrela pending approval. Iluvien, Netildex, Tenapanor & 2 x TX pending submission. http://www.gud-knight.com/wp-content/uploads/KTI_Corporate_Presentation_November_2018.pdf Link to comment Share on other sites More sharing options...
snowball82 Posted November 27, 2018 Share Posted November 27, 2018 New presentation. Probuphine lauched in Q4 2018. Ibsrela pending approval. Iluvien, Netildex, Tenapanor & 2 x TX pending submission. http://www.gud-knight.com/wp-content/uploads/KTI_Corporate_Presentation_November_2018.pdf Knight Therapeutics Announces Canadian Regulatory Approval for ILUVIEN® MONTREAL, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved ILUVIEN® for the treatment of diabetic macular edema (DME). ILUVIEN is a fluocinolone acetonide sustained release non-biodegradable intravitreal implant used to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Knight entered into an exclusive Canadian agreement for ILUVIEN with Alimera Sciences, Inc. ("Alimera") in July 2015. "The approval of ILUVIEN is great news for Canadian DME patients, payors and healthcare providers. ILUVIEN represents a well-studied, proven effective treatment for DME patients who can benefit from CONTINUOUS MICRODOSING without the burden of frequent injections," said Jonathan Ross Goodman, CEO of Knight. "We are eager to work with all payors and stakeholders across Canada to make ILUVIEN available to Canadian patients." "We are excited that ILUVIEN has received approval by Health Canada," said Dan Myers, CEO of Alimera. "ILUVIEN is the only treatment approved in Canada with CONTINUOUS MICRODOSING that can treat DME every day for up to three years with a single implant. We look forward to working with Knight to make ILUVIEN available to Canadian patients." About ILUVIEN www.ILUVIEN.com ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. and Canada to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months to treat DME. ILUVIEN has also received marketing authorization approvals in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom for the treatment of vision impairment associated with chronic diabetic macular edema (DME), considered insufficiently responsive to available therapies. ILUVIEN is available commercially in the U.S., Germany, the U.K., Austria, Ireland, Portugal, Spain, Italy, and the U.A.E. About Diabetic Macular Edema (DME) DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight's shares trade on TSX under the symbol GUD. For more information about Knight, please visit the company's web site at www.gud-knight.com or www.sedar.com. Forward-Looking Statements This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2017. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. Contact Information Knight Therapeutics Inc. Samira Sakhia President and Chief Financial Officer 514-484-4483 514-481-4116 (FAX) info@gudknight.com www.gudknight.com Link to comment Share on other sites More sharing options...
snowball82 Posted January 12, 2019 Share Posted January 12, 2019 Knight Therapeutics Runs with Exclusive Canadian License to Puma's NERLYNX® MONTREAL, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, today announced it has entered into an exclusive License Agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) ("Puma") granting Knight the exclusive right to commercialize NERLYNX® (neratinib) in Canada. Puma filed a New Drug Submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Under the terms of the License Agreement, Knight will be responsible for all commercial activities and future regulatory submissions for NERLYNX® in Canada. Puma will receive upfront and milestone payments up to $7.2 million USD throughout the term of this agreement, as well as double digit royalties on net sales of NERLYNX® in Canada. "We are excited to partner with Puma to offer a new treatment option to Canadian breast cancer patients," said Jonathan Ross Goodman, Chief Executive Officer of Knight. "While adjuvant trastuzumab-based therapy has been shown to reduce the risk of recurrence in early stage HER2-positive breast cancer, up to 25% of patients treated with adjuvant trastuzumab will have a recurrence. NERLYNX® has been shown to significantly reduce the risk of recurrence in those patients who were previously treated with trastuzumab." "Our new agreement with Knight demonstrates our commitment to bringing NERLYNX® to patients around the world while continuing to focus our commercial resources on the U.S. market," stated Alan H. Auerbach, Chief Executive Officer and President of Puma. "We are confident this new partnership will help patients in Canada access NERLYNX® at the earliest opportunity." About NERLYNX® NERLYNX® is potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. NERLYNX® was approved by the FDA in the United States in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. In September 2018, NERLYNX® was approved by the European Commission for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. For more information about Puma, please visit the corporate website at www.pumabiotechnology.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gudknight.com or www.sedar.com. Knight Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2017. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. Link to comment Share on other sites More sharing options...
snowball82 Posted January 12, 2019 Share Posted January 12, 2019 It seems to be a significant one for US : ..."For the year, Puma kept guidance for $175 million to $200 million in sales. This is attainable, MacKay said. Before the report, the Street had modeled $217 million for the year...." https://www.investors.com/news/technology/puma-stock-nerlynx-sales-top/ Link to comment Share on other sites More sharing options...
no_free_lunch Posted January 12, 2019 Share Posted January 12, 2019 It is good to see. Canada is 1/9 the size of the US, so maybe $25-30m sales potential here? The agreement says double digit royalty payments, so after they pay out milestones maybe 75-80% or $20-24m gross margin once they build it out. It will definitely help. They are already not much over book so you would be getting those royalty payments at about 4x EBITDA and any future developments plus their in-progress products for free. Link to comment Share on other sites More sharing options...
snowball82 Posted February 18, 2019 Share Posted February 18, 2019 They will have to update the new presentation ! https://www.gud-knight.com/wp-content/uploads/KTI_Corporate_Presentation_February_2019.pdf MONTREAL and BERWYN, Pa., Feb. 18, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8 Inc. ("Moksha8"), a specialty pharmaceutical company focused on licensing and marketing innovative and established therapeutics in Latin America, today announced the closing of a strategic financing agreement for up to US$125 million. MOKSHA8_3.png Under the agreement, Knight will initially lend Moksha8 up to US$25 million in working capital funding, of which US$10 million will be issued at closing. Knight may issue up to an additional US$100 million in funding for M&A and the acquisition of new licenses. "We are thrilled with this partnership", said Joel Barlan, Chief Executive Officer of Moksha8. "Moksha8 is entering a new era of growth, supported by both a talented team and significant product launches. Knight's partnership provides the fuel for the expansion of our strategy to the next level." "We are excited to partner with the new Moksha8", said Jonathan Ross Goodman, Chief Executive Officer of Knight. "Knight and Moksha8 share the common vision of bringing much needed therapeutics to underserved markets such as Canada and Latin America." As a result of the deal, Knight has the right to appoint two observers to Moksha8's Board. "We view the Board collaboration as a crucial part of the agreement", said Daniel K. Turner III, founder of Montreux Equity Partners, Moksha8's majority shareholder. "Combining Moksha8's deep market and commercial knowledge with Knight's exceptional track record as a licensee and acquirer boosts Moksha8's capabilities to new levels". Stifel, Nicolaus & Company, Incorporated (NYSE: SF) acted as financial advisor and exclusive financing agent to Moksha8 for this transaction. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gudknight.com or www.sedar.com. About Moksha8 Moksha8 is a specialty pharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in the two largest Latin America markets: Brazil and Mexico. Moksha8 is a Montreux Equity Partners portfolio company. https://www.b2i.us/profiles/investor/NewsPrint.asp?v=6&b=2320&ID=89723&m=rl&g=1058 Link to comment Share on other sites More sharing options...
snowball82 Posted February 20, 2019 Share Posted February 20, 2019 Another news today for very patient investors. We can’t ignore the fact they now target many countries. https://globenewswire.com/news-release/2019/02/20/1738806/0/en/Knight-Therapeutics-and-Triumvira-Immunologics-Triumphantly-Announce-Secured-Bridge-Loan-License-Agreement.html Link to comment Share on other sites More sharing options...
snowball82 Posted March 10, 2019 Share Posted March 10, 2019 GUD stock price now close to book value. Knight Therapeutics Comments on Flawed Accusations by Disgruntled Board Member; Remains Committed to Executing Strategy that is Working Knight Therapeutics Responds to Meir Jakobsohn's Open Letter https://www.b2i.us/profiles/investor/NewsPrint.asp?v=6&b=2320&ID=89787&m=rl&g=1058 https://www.b2i.us/profiles/investor/NewsPrint.asp?v=6&b=2320&ID=89868&m=rl&g=1058 Link to comment Share on other sites More sharing options...
wisowis Posted March 10, 2019 Share Posted March 10, 2019 Wonder if Medison is selling off its 7% stake in Knight? Recent trading volume seems higher than usual... Link to comment Share on other sites More sharing options...
clutch Posted March 25, 2019 Share Posted March 25, 2019 It seems to be trading at the book value now due to the ongoing infighting (now a lawsuit) https://www.b2i.us/profiles/investor/NewsPrint.asp?v=6&b=2320&ID=89956&m=rl&g=1058 Does anyone have any insight into this matter? Link to comment Share on other sites More sharing options...
wisowis Posted March 31, 2019 Share Posted March 31, 2019 Looks like Jonathan Goodman bought over 100k shares in the open market last week https://www.canadianinsider.com/node/7?menu_tickersearch=GUD+%7C+Knight+Therapeutics Link to comment Share on other sites More sharing options...
wisowis Posted April 9, 2019 Share Posted April 9, 2019 Jonathan Goodman interview on BNN on Friday last week: https://www.bnnbloomberg.ca/video/knight-therapeutics-ceo-i-made-a-mistake-in-selecting-my-partner~1652451 Link to comment Share on other sites More sharing options...
snowball82 Posted June 27, 2019 Share Posted June 27, 2019 Jun 26, 2019 Knight Announces Filing of New Drug Submission for Ibsrela™ in Canada https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=6&b=2320&ID=90849&m=rl&g=1058 Link to comment Share on other sites More sharing options...
snowball82 Posted June 28, 2019 Share Posted June 28, 2019 Mr Beaudet left Cipher recently. https://ca.finance.yahoo.com/news/cipher-pharmaceuticals-reports-voting-results-123000793.html Link to comment Share on other sites More sharing options...
snowball82 Posted June 28, 2019 Share Posted June 28, 2019 Next months should be very interesting. GUD own 28 % of Medison. This is not a typo. https://www.gud-knight.com/wp-content/uploads/KTI_Corporate_Presentation_2019-05-16-vF2.pdf https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/medison-establishes-canadas-only-innovative-pharma-commercial-company Link to comment Share on other sites More sharing options...
snowball82 Posted July 8, 2019 Share Posted July 8, 2019 http://www.globenewswire.com/news-release/2019/07/08/1879781/0/en/Knight-Announces-Normal-Course-Issuer-Bid.html Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now